Abstract: The present invention relates to an antagonist or inhibitor of G protein-coupled receptor 84 (GPR84) for use in the treatment and/or prevention of a patient suffering from, at risk of developing, and/or being diagnosed for endometriosis, as well as methods of screening for such antagonist or inhibitor as well as methods for diagnosis.

Abstract: The present invention relates to an androgen-dependent 1-f-aromatase reporter gene and a method for the production of the 1-f-aromatase-reporter gene and use thereof in a method for identifying ligands of the androgen receptor.

Abstract: Novel co-modulator proteins, designated ARAP3 polypeptides, for nuclear receptors, especially the androgen receptor, are described, which are useful in methods of detecting and treating steroid hormone-dependent diseases that are due to a deficiency of these co-modulator proteins. By measuring the levels of ARAP3 polypeptide expression in tissue samples from an individual a steroid hormone-dependent disease, such as breast cancer, can be detected. The levels of ARAP3 polypeptide expression in the tissue samples can be measured by immunohistochemistry methods, by ELISA methods, by radioimmuno tests, by Northern blot techniques, or by Western blot techniques A method of treating steroid hormone-dependent diseases due to a deficiency of an ARAP3 co-modulator protein in various tissues of an individual includes incorporating ARAP3 co-modulator protein in the tissues using a vector.

Abstract: In the method of determining hormonal effects of substances, a test substance is contacted with Ewing sarcoma protein (EWS) or a derivative of it and with an androgen receptor (NR) or a derivative of it; and the effect of the test substance on binding of EWS with the androgen receptor or its derivative or on ligand-induced activity of the androgen receptor is determined, preferably in a cellular system. A method for determining interference in the co-modulator mechanism between androgen receptor and EWS, which includes measurement of androgen receptor and EWS concentrations, is described. A method for identification and characterization of substances that influence the activity of a nuclear receptor, especially androgen receptor, using EWS or a derivative of it is disclosed.

Abstract: The method for testing of substances for hormonal effects, especially for androgenic or anti-androgenic effects, includes exposing cells transfected with two vectors to the substances, wherein one vector contains a DNA, which codes for a nuclear receptor protein, or a fragment thereof, especially a human nuclear receptor protein, or a fragment thereof, and the other vector contains a DNA, which codes for the HSRNAAM co-modulator, or a fragment thereof; and measuring transcription activity, which the nuclear receptor protein, or its fragment, activates or releases in the presence of the HSRNAAM co-modulator, or its fragment, and/or measuring the influence of the substance on the interaction between the nuclear receptor protein, or its fragment, and the HSRNAAM co-modulator, or its fragment, by protein-protein interaction or by protein-protein-DNA interaction. Also a method for determining interference in the co-modulation mechanism between androgen receptor protein and HSRNAAM co-modulator is described.

Abstract: In the method of determining hormonal effects of substances, a test substance is contacted with Ewing sarcoma protein (EWS) or a derivative of it and with a nuclear receptor (NR) or a derivative of it; and the effect of the test substance on binding of EWS with the nuclear receptor or its derivative or on ligand-induced activity of the nuclear receptor is determined, preferably in a cellular system. A method for determining interference in the co-modulator mechanism between androgen receptor and EWS, which includes measurement of androgen receptor and EWS concentrations, is described. A method for identification and characterization of substances that influence the activity of a nuclear receptor, especially androgen receptor, using EWS or a derivative of it is disclosed.

Abstract: The method for testing of substances for hormonal effects, especially for androgenic or anti-androgenic effects, includes exposing cells transfected with two vectors to the substances, wherein one vector contains a DNA, which codes for a nuclear receptor protein, or a fragment thereof, especially a human nuclear receptor protein, or a fragment thereof, and the other vector contains a DNA, which codes for the FOXG1C co-modulator, or a fragment thereof; and measuring transcription activity, which the nuclear receptor protein, or its fragment, activates or releases in the presence of the FOXG1C co-modulator, or its fragment, and/or measuring the influence of the substance on the interaction between the nuclear receptor protein, or its fragment, and the FOXG1C co-modulator, or its fragment, by protein-protein interaction or protein-protein-DNA interaction. Further a method for determining interference in the co-modulation mechanism between androgen receptor protein and FOXG1C co-modulator is described.

Abstract: The method for testing of substances for hormonal effects, especially for androgenic or anti-androgenic effects, includes exposing cells transfected with two vectors to the substances, wherein one vector contains a DNA, which codes for a nuclear receptor protein, or a fragment thereof, especially a human nuclear receptor protein, or a fragment thereof, and the other vector contains a DNA, which codes for the HSRNAAM co-modulator, or a fragment thereof; and measuring transcription activity, which the nuclear receptor protein, or its fragment, activates or releases in the presence of the HSRNAAM co-modulator, or its fragment, and/or measuring the influence of the substance on the interaction between the nuclear receptor protein, or its fragment, and the HSRNAAM co-modulator, or its fragment, by protein-protein interaction or by protein-protein-DNA interaction. Also a method for determining interference in the co-modulation mechanism between androgen receptor protein and HSRNAAM co-modulator is described.

Abstract: A method for testing the hormonal effect, especially the androgenic or antiandrogenic effect, of substances is described, in which (a) cells which are transfected with two vectors, one of these vectors containing DNA which codes for a nuclear receptor protein or a fragment thereof, whereas the other vector contains DNA which codes for a co-modulator or a fragment thereof, are exposed to the substance; and (b) the transcription activity which the nuclear receptor or its fragment induces in the presence of the co-modulator or its fragment and/or the effect of the substance on the interaction between the receptor or its fragment and the co-modulator or its fragment is measured by the protein-protein interaction or the protein-protein-DNA interaction. In addition, a method for determining defects in the co-modulation mechanism and means suitable for performing this method are provided.

Abstract: A testing system for identifying effectors of polypeptides (ARAP3 variants) having the respective amino acid sequences represented in Seq. ID Nos. 14 to 18 and 20. In this test system a reporter gene is expressed in a cell transfected with a nucleic acid or in a cell transfected with a vector containing at least one copy of this nucleic acid; the cell, if it contains no nuclear receptor or only a small amount thereof, is also transfected with a vector containing DNA of the nuclear receptor; the cell is cultured in the presence of a plurality of test substances and a change in expression of the reporter gene is measured to find the effectors. The nucleic acid codes one of the polypeptides (ARAP3 variants), or has a nucleotide sequence represented in one of Seq. ID Nos. 1 to 13 and 19, or has a nucleotide sequence hybridized with one of Seq. ID Nos. 1 to 13 and 19 and/or one of the nucleic acid sequences coding polypeptides with an amino acid sequence represented in one of Seq. ID Nos.

Abstract: The invention relates to a cloned gene encoding a protein which co-activates hormonal receptors, in particular the androgen receptor, in humans and relates, in addition, to the use of the co-activator protein as an important constituent in clinical tests for diagnoses of human clinical conditions.